Shreehas Tambe promoted as Deputy CEO of Biocon Biologics
March 01, 2021
×
Biocon Biologics Ltd, a subsidiary of Biocon Ltd, has promoted Shreehas Tambe to the position of Deputy Chief Executive Officer of Biocon Biologics Limited effective from March 1.
A Biocon veteran, Tambe joined Biocon in 1997 and has, since then, taken on positions of increasing responsibility and has over 20 years of leadership experience in operational and strategic roles and has led large, diverse teams at R&D, manufacturing and projects & engineering during his tenure.
Prior to becoming the Deputy CEO, Tambe was the Chief Operating Officer and a key member of the Executive Leadership Team at Biocon Biologics.
February 16, 2021
×
The partnership with IDF coincides with the start of the centenary celebrations of the discovery of insulin and takes forward Biocon Biologics’ mission of enabling affordable access to insulins to people with diabetes worldwide
Biocon Biologics Limited, a subsidiary of Biocon Ltd, has partnered with The International Diabetes Federation (IDF) as the first biosimilar insulins company to promote and support IDF’s Core Mission initiative and activities.
The partnership with IDF coincides with the start of the centenary celebrations of the discovery of insulin and takes forward Biocon Biologics’ mission of enabling affordable access to insulins to people with diabetes worldwide, the company said in a release.
Updated Jan 22, 2021 | 12:00 IST
Shares of Biocon saw a steep fall after the drugmaker s results missed analyst estimates in the quarter ended December. Net profit declined 19% year-on-year as expenses rose significantly. Biocon earnings | Photo Credit: BCCL
Key Highlights
Biocon says it continues to face headwinds across operational, regulatory and commercial function Dr. Christiane Hamacher steps down as the Managing Director of Biocon Biologics Limited due to professional differences with the Chairperson on strategic priorities and vision for the company
Mumbai: Biocon was one of the top laggards on Dalal Street today as the company declared it’s earnings, however, the earnings were a miss compared to the consensus street estimates that were pencilled in. Below are the key highlights of the earnings report by Biocon.
Biocon Biologics reports topline of ₹769 crore in Q3
January 22, 2021
The subsidiary of Biocon Ltd raised raised $330 million in the quarter, says CEO Hamacher
Biocon Biologics Limited, a subsidiary of Biocon Limited, has seen revenue growth in Q3 FY21 mainly driven by steady marketshare of products in the US and growth in key MoW markets including AFMET and India.
“Through our partners, we continue to expand sales for rHI (recombinant human insulin) in key markets like Mexico and Malaysia, and Insulin Glargine in Algeria and Malaysia. We continue to be the leading player for biosimilar Trastuzumab in Brazil’s private market and are reporting strong performance in other markets like Turkey and Algeria,” said Christiane Hamacher, CEO, Biocon Biologics Ltd.
“2020 has been one of the most challenging years for the world with an unprecedented pandemic impact on the global economy. We continue to face headwinds across operational, regulatory and commercial functions which have been deterrents to our planned market expansion. However, we expect normalization by next fiscal,” said Kiran Mazumdar-Shaw, executive chairperson, Biocon.